



Extraordinary General Meeting Proxy Voting Results

Asterand plc (LSE: ATD), a leading provider of human tissue and human tissue-based research services to pharmaceutical and biotechnology companies engaged in drug discovery research, held an Extraordinary General Meeting (EGM) at 17.30 (BST) on Tuesday 8 June 2010 in London, immediately following the Company's Annual General Meeting.

All of the following resolutions set out in the Notice of Meeting sent to Shareholders on 14 May 2010 were duly passed at the EGM.

Proxy votes on the resolutions were as follows:

		For (including discretionary)	Against	Vote Withheld
	Ordinary Resolutions			
1.	To authorise the Directors to implement the Growth Share Ownership Plan	45,761,880	7,544,808	7,122,532
2.	To amend the Long Term Incentive Plan	42,602,111	10,709,577	7,117,532
	Special Resolutions			
3.	To allow General Meetings, other than the Annual General Meeting, to be called on not less than 14 clear days' notice	59,541,034	877,386	10,800

Contacts:

Asterand plc

Martyn Coombs, Chief Executive Officer

Tel: + 44 (0) 1763 211 600 /
+ 1 (313) 263-0960
As above

John Stchur, Chief Financial Officer

Buchanan Communications

Lisa Baderon / Mark Court / Isabel Podda

Tel: +44 (0) 20 7466 5000

Cenkos Securities plc

Stephen Keys / Beth McKiernan

Tel: + 44 (0) 20 7397 8924

Daniel Stewart & Company plc

Martin Lampshire

Tel: +44 (0) 20 7776 6550

About ASTERAND

Asterand plc is a leading supplier of high quality human tissue and tissue-based services. Our comprehensive approach to human tissue and research services offers pharmaceutical, biotech and diagnostic companies the unique opportunity to have one company meet all of their human biomaterial needs along the continuum of drug discovery and development. Our mission is to accelerate target discovery and compound validation and enable pharmaceutical and biotechnology companies to take safer and more effective drugs into the market.

For more information, go to www.asterand.com.